Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients (Q30655745)

26 June 2017

0 references

Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients (English)

1 reference

26 June 2017

1 reference

1 reference

Myeloma Trialists' Collaborative Group

series ordinal

1

1 reference

PubMed ID

11442498

26 June 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

British Journal of Haematology

26 June 2017

1 reference

26 June 2017

113

1 reference

26 June 2017

4

1 reference

26 June 2017

1020-1034

1 reference

Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).

26 June 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02857.X

Systematic reviews using individual patient data: a map for the minefields?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02857.X

Interferons in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02857.X

A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02857.X

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02857.X

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02857.X

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02857.X

Australian Leukaemia Study Group myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02857.X

Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02857.X

Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02857.X

The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02857.X

Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02857.X

Meta-analysis of the literature or of individual patient data: is there a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02857.X

Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02857.X

10.1046/J.1365-2141.2001.02857.X

21 January 2018

Identifiers

DOI

1 reference

26 June 2017

1 reference

PubMed ID

11442498